Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.
Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.
复制标题
DOI：
10.2147/dddt.s119545
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Udeani G
中科院分区：
文献类型：
--
作者：
Donald BJ;Surani S;Deol HS;Mbadugha UJ;Udeani G
社区获得性细菌性肺炎（CABP）是世界范围内的主要死亡原因。然而，用于治疗CABP常见病原体的抗菌药物的特点是不良药物事件和耐药性增加。索利霉素是一种新的酮内酯类抗生素，基于大环内酯类抗生素结构，正在研究用于CABP。它在体外对CABP中的常见致病病原体（包括肺炎链球菌、流感嗜血杆菌和非典型病原体）有效。在II期和III期临床试验中，它已被证明是治疗CABP的有效单药，其不良事件特征明显比替代药物更轻。
Community-acquired bacterial pneumonia (CABP) is a leading cause of death worldwide. However, antibacterial agents used to treat common pathogens in CABP are marked by adverse drug events and increasing antimicrobial resistance. Solithromycin is a new ketolide antibiotic, based on the macrolide antibiotic structure, being studied for use in CABP. It has efficacy in vitro against the common causative pathogens in CABP including Streptococcus pneumoniae, Haemophilus influenzae, and atypical pathogens. In Phase II and Phase III clinical trials, it has been demonstrated efficacious as a single agent for treatment of CABP with an apparently milder adverse event profile than alternative agents.